All manuscripts
Publications VST Cells

Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients

Published Journal Journal for ImmunoTherapy of Cancer

Share
1 page Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients — Journal for ImmunoTherapy of Cancer, 2013

Overview

This abstract reports the clinical use of rapidly generated pentavalent virus-specific T cells expanded in G-Rex® devices. The single-stimulation G-Rex® protocol produced sufficient cells in 10 days to safely and effectively treat drug-refractory EBV, CMV, Adv, BK, and HHV6 infections in HSCT patients.

What this paper found

Donor-derived pentavalent T cell lines targeting five viruses (EBV, adenovirus, CMV, BK and HHV6) were generated rapidly and infused into stem cell transplant recipients, proving safe so far and associated with virus clearance. Lines were stimulated once with peptide libraries and expanded with IL4+7 in a G-Rex® device; from 30×10^6 PBMCs, a mean of 374×10^6 cells was obtained over 9-11 days, with 35 clinical-grade lines generated. The cells were polyclonal, with CD4+ 57±5% and CD8+ 35±5%, and showed no alloreactivity against recipient PHA blasts. Ten patients on study received cells at three dose levels with no adverse events; by day 42, viral load showed control of active CMV, EBV, Adv, BK and HHV6 infections.

Note: Interim report from an ongoing dose-escalation study with 10 patients treated to date.

In summary, infusion of pCTLs has thus far proven safe and is associated with the appearance of virus-reactive T cells in peripheral blood and subsequent virus clearance. — Anastasia Papadopoulou, Usha Katari, Ulrike Gerdemann, Caridad Martinez, Kathy Leung, George Carrum, Adrian Gee, Juan Vera, Robert Krance, Malcolm Brenner, Cliona Rooney, Helen Heslop, Ann Leen, Journal for ImmunoTherapy of Cancer

Study details

Authors
Anastasia Papadopoulou, Usha Katari, Ulrike Gerdemann, Caridad Martinez, Kathy Leung, George Carrum, Adrian Gee, Juan Vera, Robert Krance, Malcolm Brenner, Cliona Rooney, Helen Heslop, Ann Leen
Institution
Baylor College of Medicine, Houston, TX, USA · Texas Children's Hospital, Houston, TX, USA · The Methodist Hospital, Houston, TX, USA
Journal
Journal for ImmunoTherapy of Cancer
Year
2013
PMID / PMC
PMC
Cell type(s)
VST Cells
Application area
Infectious disease

How G-Rex® was used

Donor-derived pentavalent T cell lines were stimulated once with peptide libraries and expanded with IL4+7 in a G-Rex® device. From 30×10^6 PBMCs, a mean of 374×10^6 cells (range 99-713×10^6) was obtained over 9-11 days for clinical-grade lines.

Explore related

Full citation

Papadopoulou A, Katari U, Gerdemann U, et al. Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients. J Immunother Cancer. 2013;1(S1):O2.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →